ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight

MONDAY, June 23, 2025 (HealthDay News) -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist, ecnoglutide, yields a superior and sustained reduction in body weight versus placebo, according to a study published online June 21 in The Lancet Diabetes & Endocrinology to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.Linong Ji, M.D., from the Peking University People's Hospital in Beijing, and colleagues examined the efficacy and safety of once-weekly ecnoglutide versus placebo for the treatment of overweight or obesity. Participants, aged 18 to 75 with overweight or obesity, without diabetes, were randomly assigned to receive subcutaneous ecnoglutide (1.2, 1.8, or 2.4 mg; 166, 166, and 167 participants, respectively) or volume-matched placebo (165 participants), once weekly.The researchers found that the least-squares mean percentage change in body weight at week 40 was −9.1, −10.9, and −13.2 percent in the ecnoglutide 1.2-, 1.8-, and 2.4-mg groups, respectively, versus 0.1 percent in the placebo group. The proportion of participants who achieved at least a 5 percent reduction in body weight at week 40 was 77, 84, and 87 percent in the ecnoglutide 1.2-, 1.8-, and 2.4-mg groups, respectively, versus 16 percent in the placebo group. Treatment-emergent adverse events were observed in 93 percent in each ecnoglutide dose group and in 84 percent in the placebo group."These findings suggest ecnoglutide is a potent therapeutic option for individuals with overweight or obesity, particularly considering its extended dosing range enabling personalized weight management strategies," the authors write.The study was funded by Hangzhou Sciwind Biosciences, which is developing ecnoglutide.Abstract/Full Text (subscription or payment may be required)Editorial (subscription or payment may be required)More Information.Sign up for our weekly HealthDay newsletter